PDF(Pubmed)
Abstract：
Both sotorasib and adagrasib are approved for use in metastatic KRASG12C-mutated NSCLC after cancer progression on chemotherapy and immunotherapy. Hepatoxicity is a commonly encountered adverse effect of both agents, and little data exists about the safety of sequential use of these agents when hepatotoxicity is encountered. In this case report, we describe a patient who developed recurrent hepatotoxicity with sotorasib and was able to switch to adagrasib without hepatotoxicity and subsequently experienced a prolonged cancer response. We also describe a previously unreported adagrasib adverse effect of photoinduced skin hyperpigmentation.
摘要：
sotorasib和adagrasib均被批准用于化疗和免疫治疗癌症进展后的转移性KRASG12C突变的NSCLC。肝毒性是两种药物的常见不良反应，当遇到肝毒性时，关于连续使用这些药物的安全性的数据很少。在这个案例报告中,我们描述了一个患者,他出现了复发性肝毒性与索托拉西布,并能够转换为adagrasib没有肝毒性,随后经历了一个长期的癌症反应.我们还描述了以前未报道的adagrasib光致皮肤色素沉着过度的不良反应。
